spacer
The Healthcare Sales & Marketing Network celebrates 25 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  CORLUX 

 HSMN NewsFeed - 30 Jun 2011
FDA Accepts Submission of New Drug Application for CORLUX for Cushing's Syndrome
Biopharmaceuticals FDA
 HSMN NewsFeed - 22 Dec 2010
Corcept Therapeutics Announces Positive Phase 3 Study Results for CORLUX for the Treatment of Cushing's Syndrome
Biopharmaceuticals
 HSMN NewsFeed - 16 Sep 2010
Steven Lo Joins Corcept as Vice President of Commercial Operations
Biopharmaceuticals Personnel
 HSMN NewsFeed - 5 Jan 2010
Corcept Therapeutics Announces Four Anticipated Milestones for 2010
Biopharmaceuticals
 HSMN NewsFeed - 2 Dec 2008
Caroline Loewy Joins Corcept as Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 24 Mar 2008
Corcept Therapeutics Announces Commencement of Next Phase 3 Study With CORLUX(R) for the Treatment of Psychotic Depression
Biopharmaceuticals
 HSMN NewsFeed - 17 Mar 2008
Corcept Therapeutics Announces $25.3 Million Private Equity Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 11 Sep 2007
Corcept Therapeutics Receives FDA Notification Opening IND for CORLUX(R) for the Treatment of Cushing's Syndrome
Biopharmaceuticals
 HSMN NewsFeed - 20 Aug 2007
Corcept Therapeutics Announces $10.1 Million Private Equity Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 9 Jul 2007
Corcept Therapeutics Receives Orphan Drug Designation for CORLUX(R) Treatment of Cushing's Syndrome
Biopharmaceuticals FDA
 HSMN NewsFeed - 30 Mar 2007
Corcept Therapeutics Announces $9 Million Private Equity Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 28 Mar 2007
Corcept Therapeutics Announces Chief Financial Officer Resignation
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 Mar 2007
Corcept Therapeutics Announces Phase 3 Study Evaluating CORLUX(R) for Psychotic Major Depression Misses Primary Endpoint
Biopharmaceuticals
 HSMN NewsFeed - 13 Nov 2006
Corcept Therapeutics Completes Enrollment in Third Phase 3 Study for Treating Psychotic Major Depression
Biopharmaceuticals
 HSMN NewsFeed - 29 Sep 2006
Corcept Therapeutics Announces Negative Results From the Second of Three Phase 3 Studies Evaluating CORLUX(R) for Treating the Psychotic Features of Psychotic Major Depression
Biopharmaceuticals
 HSMN NewsFeed - 25 Aug 2006
Corcept Therapeutics Announces Negative Results From the First of Three Phase 3 Studies Evaluating CORLUX(R) for Treating the Psychotic Features of Psychotic Major Depression
Biopharmaceuticals
 HSMN NewsFeed - 22 May 2006
Corcept Therapeutics Completes Enrollment in Second Phase 3 Study for Treating Psychotic Major Depression
Biopharmaceuticals
 HSMN NewsFeed - 1 May 2006
Corcept Therapeutics Completes Enrollment in Phase 3 Study for Treating Psychotic Major Depression
Biopharmaceuticals
Return to NewsFeed  

 Additional items found! 3

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 3 additional stories matching:
CORLUX
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.